Citius Oncology Q2 net loss widens to $7.7M; cash only $112, needs funding beyond May 2025

CITIUS ONCOLOGY, INC.

2025-Q2 EPS reported -$0.20 vs consensus -$0.15 ▼ miss (-30.7%)

Net loss of $7.7M ($0.11 per share) vs $4.8M loss a year ago; R&D and G&A expenses increased due to launch activities.
Cash and equivalents at March 31, 2025 totaled just $112; company requires additional capital to sustain operations beyond May 2025.
Retained Jefferies LLC as exclusive financial advisor to evaluate strategic alternatives aimed at maximizing stockholder value.
Advancing commercial launch of LYMPHIR (cutaneous T-cell lymphoma) after FDA approval; discussions with partners ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.